A5030730159- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- PI3K/AKT/mTOR signaling in cancer
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Retinal Diseases and Treatments
- Uterine Myomas and Treatments
- PARP inhibition in cancer therapy
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Neutropenia and Cancer Infections
- Nuclear Structure and Function
- Blood disorders and treatments
- Economic and Financial Impacts of Cancer
- Lung Cancer Research Studies
- Ubiquitin and proteasome pathways
- Viral-associated cancers and disorders
- Intraperitoneal and Appendiceal Malignancies
- Multiple and Secondary Primary Cancers
- Colorectal Cancer Treatments and Studies
- Glycosylation and Glycoproteins Research
- Ovarian cancer diagnosis and treatment
University of Cincinnati Medical Center
2016-2021
University of Cincinnati
2012-2021
Sabin Vaccine Institute
2018
Studies of the estrogen receptor (ER) coactivator protein Mediator subunit 1 (MED1) have revealed its specific roles in pubertal mammary gland development and potential contributions to breast tumorigenesis, based on coamplification MED1 HER2 certain cancers. In this study, we generated a mouse model tumorigenesis harboring MMTV-HER2 oncogene mutation evaluate role HER2-driven tumorigenesis. ER-interacting LxxLL motifs was sufficient delay tumor onset impair growth, metastasis, cancer...
MED1 (mediator subunit 1) co-amplifies with HER2, but its role in HER2-driven mammary tumorigenesis is still unknown. Here, we generate mammary-specific overexpression mice and cross them mouse tumor virus (MMTV)-HER2 mice. We observe significantly promoted onset, growth, metastasis, multiplicity of HER2 tumors by overexpression. Further studies reveal critical roles for epithelial-mesenchymal transition, cancer stem cell formation, response to anti-HER2 therapy. Mechanistically, RNA...
TPS1102 Background: There is no standard of care for HER2-positive breast cancer refractory to T-DM1. DS-8201a a novel HER2-targeted antibody-drug conjugate with humanized HER2 antibody attached topoisomerase I inhibitor payload by cleavable peptide-based linker (deruxtecan), and high drug-to-antibody ratio 7 8. In the ongoing phase 1 DS8201-A-J101 trial, showed manageable safety profile promising antitumor activity in subjects previously receiving T-DM1 (confirmed objective response rate...
TPS3116 Background: Downregulation of a number signaling pathways, including the mammalian target rapamycin (mTOR) pathway, has been demonstrated to be efficacious in large range solid tumors such as breast, colon, endometrial, glial and hepatocellular carcinoma (HCC). However, we find that rapamycins lead suppression negative feedback loop from S6 Kinase 1 (S6K1) Protein B (PKB), leading hyperactivation PKB. In pre-clinical studies using mouse model carcinogen-induced HCC, have combining...
Abstract Background: Fulvestrant is a well-established treatment for postmenopausal patients with estrogen receptor (ER) positive metastatic breast cancer, and some experience prolonged clinical benefit exceeding one year. HER2 activation major cause of endocrine resistance, cross-talk between HER2/neu ER coactivator MED1 regulates tamoxifen resistance in cancer cells. (Cancer Res 2012 1;72(21):5625-34.). In xenograft mouse model, suppression enhanced tumor growth inhibition by fulvestrant...
e12621 Background: Tumor infiltrating lymphocytes (TILs) are thought to represent favorable host anti-tumor immunity and play an important role in mediating response chemotherapy breast cancer. TILs heterogenous across cancer subtypes increasingly being studied as prognostic predictive biomarkers. We undertook a retrospective study establish the relationship between pre-treatment density of subsequent quality neoadjuvant patients with early-stage Methods: retrospectively identified women who...
e19543 Background: Post-transplant lymphoproliferative disorder (PTLD) is a rare and potentially fatal complication of chronic immunosuppression in solid organ transplant (SOT) hematopoietic stem cell recipients. With an overall incidence ̃ 1 percent the recipients, it most common malignancy, with exception skin cancer, after SOT adults. There paucity information concerning outcomes prognostic indicators PTLD. Methods: We queried National Cancer Database (NCDB) from 2004 – 2015 for patients...
Division of Hematology/Oncology, Department Medicine, University Cincinnati Medical Center, Cincinnati, OH The authors have no conflicts interest to declare.
Abstract Breast cancer (BC) is one of the leading causes death for women in United States. This due, part, because wait too long to get a diagnosis or disease returns, sometimes years later, due ineffective treatment. Therefore, it critically important identify biomarkers that can better inform clinicians while providing screening test more amenable patients than mammograms. We are investigating feasibility using DEK protein levels patient plasma as biomarker stage and prognosis....
155 Background: Overexpression of HER2/neu is associated with tamoxifen resistance in breast cancer (Osborne CK et al. J Natl Canc Inst 2003; 95:353-361). However pts may present both estrogen receptor (ER) and + tumors. The benefit adding fulvestrant to trastuzumab unclear. objective the study was determine effect on therapy. Methods: This an IRB approved record review patients (pts) from three medical oncologists biopsy-proven ER+ metastatic treated who also had their primary tumor tested...
e11548 Background: MED1 is an estrogen receptor coactivator that associated with resistance to antiestrogen therapy, and silencing sensitizes breast cancer cells fulvestrant Cross talk between HER-2 regulates tamoxifen There a need standardize immunohistochemical (IHC) expression of in determine the prevalence overexpression Methods: This IRB approved study evaluated ER positive primary or metastatic cancers from patients treated at University Cincinnati Utilizing antibody against C-terminus...
<p>Supplementary Information - This file contains Supplemental Procedures, References, Table1, Supplementary Figure Legends, and Figures. Procedure describes the methods PCR primers used in this study. References lists references cited supplemental procedures. Table1 shows patients demographics tumor data. Legends describe legend for each supplementary figure. S1 MED1 LxxLL motif mutations reduce cell proliferation expression ER target genes grafted tumors. S2 IGF1 rescues MED1KI/KI...
<p>Supplementary Information - This file contains Supplemental Procedures, References, Table1, Supplementary Figure Legends, and Figures. Procedure describes the methods PCR primers used in this study. References lists references cited supplemental procedures. Table1 shows patients demographics tumor data. Legends describe legend for each supplementary figure. S1 MED1 LxxLL motif mutations reduce cell proliferation expression ER target genes grafted tumors. S2 IGF1 rescues MED1KI/KI...
<div>Abstract<p>Studies of the estrogen receptor (ER) coactivator protein Mediator subunit 1 (MED1) have revealed its specific roles in pubertal mammary gland development and potential contributions to breast tumorigenesis, based on coamplification MED1 HER2 certain cancers. In this study, we generated a mouse model tumorigenesis harboring MMTV-HER2 oncogene mutation evaluate role HER2-driven tumorigenesis. ER-interacting LxxLL motifs was sufficient delay tumor onset impair...
<div>Abstract<p>Studies of the estrogen receptor (ER) coactivator protein Mediator subunit 1 (MED1) have revealed its specific roles in pubertal mammary gland development and potential contributions to breast tumorigenesis, based on coamplification MED1 HER2 certain cancers. In this study, we generated a mouse model tumorigenesis harboring MMTV-HER2 oncogene mutation evaluate role HER2-driven tumorigenesis. ER-interacting LxxLL motifs was sufficient delay tumor onset impair...
BACKGROUND:Mucinous ovarian adenocarcinoma is one of the less common epithelial cancers ovaries, and typically does not occur in younger women. Nearly all mucinous adenocarcinomas present with early-stage disease without significant sequelae cancer, such as clotting. Anchoring bias a problem medicine that has been shown to significantly affect physician decision-making. CASE REPORT:We case 24-year-old healthy female Chinese immigrant no past medical history, who presented subacute history...
e13031 Background: Palbociclib is a CDK 4/6 inhibitor approved for treatment of metastatic hormone receptor positive breast cancer with therapy. We noticed variations in red cell indices patients on therapy and performed retrospective review to systematically assess change Palbociclib. Methods: identified 46 advanced (HR) positive, human epidermal growth factor 2 negative who were treated at our institution from March 2015 January 2018. The co-primary endpoint study was an increase MCV...
e19086 Background: TNBC is a heterogeneous sub-type of breast cancer characterized by younger age onset, more aggressive course, and higher incidence among African Americans who also experience disparities in access to health care including insurance coverage screening. Methods: We performed retrospective analysis the NCDB study impact race status on stage at diagnosis overall survival people with TNBC. Chi-square tests was used for univariate analysis. Cox models were test differences...